

THIS SHEET HAS BEEN
REPLACED

ABSTRACT OF THE DISCLOSURE

5 This invention relates to therapeutic reagents and peptides, including
radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides,
and methods for producing labeled radiodiagnostic agents. Specifically, the
invention relates to cyclic peptide derivatives and analogs of somatostatin, and
embodiments of such peptides radiolabeled with a radioisotope, as well as
methods and kits for making, radiolabeling and using such peptides for
radiodiagnostic and radiotherapeutic purposes. The invention specifically relates
to cyclic peptide derivatives and analogues of somatostatin radiolabeled with
10 technetium-99m and uses thereof as scintigraphic imaging agents. The
invention also specifically relates to cyclic peptide derivatives and analogues of
somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186
(¹⁸⁶Re) and rhenium-188 (¹⁸⁸Re) for use as radiotherapeutic agents. Methods
and kits for making, radiolabeling and using such peptides diagnostically and
15 therapeutically in a mammalian body are also provided.

This Sheet Has Been Replaced

